CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kite Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kite Pharma Inc
2225 Colorado Ave
Phone: (310) 824-9999p:310 824-9999 SANTA MONICA, CA  90404-3505  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 10/3/2017.
This company ceased filing statements with the SEC on 10/13/2017.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201712/31/2016YesYes-YesYes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, President, Chief Executive Officer, Founder Arie S.Belldegrun 67 3/1/2014
Chief Financial Officer Paul L.Jenkinson 57 5/16/2016 5/16/2016
Chief Operating Officer Cynthia M.Butitta 62 5/16/2016 1/1/2014
12 additional Officers and Directors records available in full report.

Business Names
Business Name
KITE
Kite Pharma EU
Kite Pharma EU B.V.
4 additional Business Names available in full report.

General Information
Number of Employees: 447 (As of 12/31/2016)
Outstanding Shares: 57,181,750 (As of 8/4/2017)
Shareholders: 40
Stock Exchange: NASD
Federal Tax Id: 271524986
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023